GERON CORP Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
GERON CORP (GERN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.74 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-02
- GERON CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.74, a 39.16% decline from fiscal 2024.
- GERON CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.86, a 5.15% increase from fiscal 2023.
- GERON CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2.72, a 98.54% increase from fiscal 2022.
- GERON CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $1.37, a 24.31% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $1.74 10-K · filed 2026-03-02 |
| 2024-12-31 | $2.86 10-K · filed 2025-02-27 |
| 2023-12-31 | $2.72 10-K · filed 2024-02-28 |
| 2022-12-31 | $1.37 10-K · filed 2023-03-16 |
| 2021-12-31 | $1.81 10-K · filed 2022-03-10 |
| 2020-12-31 | $1.37 10-K · filed 2021-03-11 |
| 2019-12-31 | $1.32 10-K · filed 2020-03-12 |
| 2018-12-31 | $2.07 10-K · filed 2019-03-07 |
| 2017-12-31 | $2.19 10-K · filed 2018-03-16 |
| 2016-12-31 | $2.56 10-K · filed 2017-03-01 |
| 2015-12-31 | $4.29 10-K · filed 2016-03-10 |
| 2014-12-31 | $4.85 10-K · filed 2015-03-11 |
| 2013-12-31 | $1.57 10-K · filed 2014-03-17 |
| 2012-12-31 | $1.51 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |